Martin Williams

Martin Williams, PhD, is Executive Director of Psychedelic Research in Science & Medicine (PRISM) and Vice-President of Entheogenesis Australis (EGA). Martin’s background is in medicinal chemistry and pharmacology, and more recently in psychedelic clinical research.

He has been a co-investigator on several Australian clinical trials of psychedelic-assisted psychotherapy, including the St Vincent’s Hospital Melbourne study of psilocybin-assisted psychotherapy in palliative care; the Monash PsiConnect neuroimaging study of psilocybin with mindfulness meditation; the Swinburne PsiloDep pilot study of psilocybin-assisted therapy for treatment-resistant depression; and the IMPACT-2 study of methylone with therapy for PTSD.